Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells

Area of Science:

• Oncology
• Regenerative Medicine
• Biotechnology

Background:

• Bone metastases are a significant clinical challenge, often leading to poor patient outcomes.
• Current treatments for bone metastases lack specificity, resulting in systemic toxicity and limited efficacy.
• A novel strategy is needed to target both cancer cells and their bone microenvironment.

Purpose of the Study:

• To develop an innovative approach for treating bone metastases.
• To engineer mesenchymal stem cells (MSCs) for targeted delivery of therapeutic agents to bone metastatic sites.
• To evaluate the efficacy and safety of these engineered MSCs in preclinical models.

Main Methods:

• Mesenchymal stem cells (MSCs) were engineered using mRNA to express homing factors (PSGL-1/SLEX) and therapeutic factors (cytosine deaminase/osteoprotegerin).
• The engineered MSCs were tested in mouse models, including a xenograft intratibial model and a syngeneic model of spontaneous bone metastasis.
• In vitro assays confirmed the production of functional proteins by the engineered MSCs.

Main Results:

• mRNA-engineered MSCs demonstrated enhanced homing to bone metastatic niches.
• The engineered MSCs effectively eliminated tumor cells and maintained bone integrity in both preclinical models.
• Engineered MSCs exhibited significantly lower toxicity compared to conventional chemotherapy (5-fluorouracil).

Conclusions:

• Combinatorial targeting of cancer cells and their niche using engineered MSCs offers a safe and effective treatment for bone metastases.
• This approach has potential for broader applications in treating various cancers and other diseases by modifying cell types and therapeutic cargos.
• The strategy represents a promising advancement in managing challenging metastatic bone diseases.